Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)
China · Delayed Price · Currency is CNY 8.58
-0.03 (-0.35%)
Apr 30, 2026, 3:04 PM CST
SHE:002693 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 276.76 | 169.49 | 231.06 | 250.33 | 303.56 |
Other Revenue | - | 4.71 | 4.87 | 24.42 | 16.74 |
| 276.76 | 174.21 | 235.93 | 274.75 | 320.29 | |
Revenue Growth (YoY) | 58.87% | -26.16% | -14.13% | -14.22% | 18.87% |
Cost of Revenue | 125.24 | 84.38 | 82.41 | 94.65 | 87.68 |
Gross Profit | 151.53 | 89.83 | 153.52 | 180.1 | 232.61 |
Selling, General & Admin | 115.59 | 143.19 | 175.23 | 202.13 | 264.62 |
Research & Development | 8.09 | 12.89 | 7.96 | 14.59 | 10.62 |
Other Operating Expenses | 3.78 | 5.35 | 6.02 | 7.71 | 7.03 |
Operating Expenses | 127.46 | 161.6 | 190.35 | 224.34 | 282.23 |
Operating Income | 24.06 | -71.77 | -36.83 | -44.24 | -49.62 |
Interest Expense | - | -9.23 | -9.58 | -11.19 | -9.03 |
Interest & Investment Income | 0.56 | 0.73 | 2.79 | 4.75 | 4.17 |
Currency Exchange Gain (Loss) | - | 0.36 | 0.12 | 0.01 | -0.1 |
Other Non Operating Income (Expenses) | -11.25 | -0.04 | -0.18 | -0.05 | -0.81 |
EBT Excluding Unusual Items | 13.37 | -79.96 | -43.69 | -50.71 | -55.39 |
Gain (Loss) on Sale of Investments | 0.01 | -10.09 | -39.85 | -0.06 | - |
Gain (Loss) on Sale of Assets | 0.01 | -0.07 | 0.79 | 29.9 | 13.74 |
Asset Writedown | -5.24 | -18.96 | - | -2.1 | - |
Other Unusual Items | - | 2.9 | 9.78 | 14.09 | 1.29 |
Pretax Income | 8.16 | -106.17 | -72.97 | -8.88 | -40.36 |
Income Tax Expense | -0.76 | 0.1 | -0.99 | -0.38 | 0.45 |
Earnings From Continuing Operations | 8.92 | -106.27 | -71.98 | -8.5 | -40.81 |
Minority Interest in Earnings | 10.12 | 27.96 | 21.23 | 17.51 | 20.48 |
Net Income | 19.04 | -78.3 | -50.74 | 9.01 | -20.33 |
Net Income to Common | 19.04 | -78.3 | -50.74 | 9.01 | -20.33 |
Shares Outstanding (Basic) | 381 | 412 | 423 | 451 | 407 |
Shares Outstanding (Diluted) | 381 | 412 | 423 | 451 | 407 |
Shares Change (YoY) | -7.59% | -2.53% | -6.16% | 10.85% | -0.91% |
EPS (Basic) | 0.05 | -0.19 | -0.12 | 0.02 | -0.05 |
EPS (Diluted) | 0.05 | -0.19 | -0.12 | 0.02 | -0.05 |
Free Cash Flow | 17.68 | -65.73 | -37.56 | -7.77 | -8.09 |
Free Cash Flow Per Share | 0.05 | -0.16 | -0.09 | -0.02 | -0.02 |
Gross Margin | 54.75% | 51.56% | 65.07% | 65.55% | 72.62% |
Operating Margin | 8.70% | -41.20% | -15.61% | -16.10% | -15.49% |
Profit Margin | 6.88% | -44.95% | -21.51% | 3.28% | -6.35% |
Free Cash Flow Margin | 6.39% | -37.73% | -15.92% | -2.83% | -2.52% |
EBITDA | 77.06 | -19.43 | 15.84 | 13.3 | 4.71 |
EBITDA Margin | 27.84% | -11.15% | 6.71% | 4.84% | 1.47% |
D&A For EBITDA | 53 | 52.34 | 52.67 | 57.54 | 54.33 |
EBIT | 24.06 | -71.77 | -36.83 | -44.24 | -49.62 |
EBIT Margin | 8.70% | -41.20% | -15.61% | -16.10% | -15.49% |
Revenue as Reported | - | 174.21 | 235.93 | 274.75 | 320.29 |
Advertising Expenses | - | 1.57 | 0.07 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.